EN / 中文
您的位置： 首页 > 2025年2月 第56卷 第2期 > 文字全文
2023年7月 第38卷 第7期11
目录

MDSCs在肿瘤免疫治疗中的研究进展

Research progress of MDSCs in tumor immunotherapy

来源期刊： 广州医药 | 151-159 发布时间：2025-03-10 收稿时间：2025/11/13 18:54:57 阅读量：33
作者：
姚远,
尹亭亭,
关键词：
肿瘤免疫治疗免疫逃逸髓系来源抑制性细胞联合治疗
tumor immunotherapyimmune evasionmyeloid-derived suppressor cells（MDSCs）combination therapy
DOI：
10.20223/j.cnki.1000-8535.2025.02.002
收稿时间：
2024-07-23 
修订日期：
 
接收日期：
 
引用总数：
1  
实体瘤对免疫治疗应答非常有限,因此,如何有效提升肿瘤免疫治疗的疗效,已成为当前肿瘤免疫治疗领域亟待解决的关键难题与挑战。髓系来源抑制性细胞（MDSCs）的趋化募集及其所介导的肿瘤免疫逃逸机制,是制约实体瘤免疫治疗效果的核心因素之一。文章深入探讨了MDSCs的起源、表型特征、其介导肿瘤免疫逃逸的具体机制,以及当前针对MDSCs的靶向治疗策略与将MDSCs靶向疗法与肿瘤免疫治疗相结合的最新研究进展。此外,文章还系统性地分析了靶向MDSCs联合免疫治疗策略所面临的关键挑战,并据此提出了MDSCs的精准靶向策略。这一策略旨在精确激活抗肿瘤免疫反应,为癌症患者提供更为个性化、高效的治疗方案,从而开启肿瘤免疫治疗领域的新纪元,为癌症治疗策略的创新与发展贡献力量。
Solid tumors exhibit a very limited response to immunotherapy．Consequently,effectively enhancing the therapeutic efficacy of tumor immunotherapy has emerged as a critical challenge and problem that urgently needs to be addressed in tumor immunotherapy．The chemotaxis and recruitment of myeloid-derived suppressor cells（MDSCs）and the tumor immune evasion mechanisms mediated by them are one of the core factors that significantly restrict the efficacy of immunotherapy for solid tumors．In this review,we discuss the origins and phenotypic characteristics of MDSCs,the specific mechanisms by which they mediate tumor immune evasion,as well as current targeted therapeutic strategies for MDSCs and the latest research progress in combining MDSC-targeted therapy with tumor immunotherapy．Furthermore,we have systematically analyzed the key challenges faced by the combination of MDSC-targeted and immunotherapy strategies,and accordingly proposed a precise targeting strategy for MDSCs．This strategy aims to precisely activate anti-tumor immune responses,providing more personalized and efficient treatment options for cancer patients,thereby opening a new era in tumor immunotherapy and contributing to the innovation and development of cancer treatment strategies．
1、 NAKAMURA K,SMYTH M J.Myeloid immunosuppression and immune checkpoints in the tumor microenvironment[J].Cell Mol Immunol,2020,17(1):1-12. NAKAMURA K,SMYTH M J.Myeloid immunosuppression and immune checkpoints in the tumor microenvironment[J].Cell Mol Immunol,2020,17(1):1-12.
2、 WANG P F,SONG S Y,WANG T J,et al.Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies:A meta-analysis of 40 studies[J].Oncoimmunology,2018,7(10):e1494113. WANG P F,SONG S Y,WANG T J,et al.Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies:A meta-analysis of 40 studies[J].Oncoimmunology,2018,7(10):e1494113.
3、 WAN S,ZHAO E,KRYCZEK I,et al.Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells[J].Gastroenterology,2014,147(6):1393-1404. WAN S,ZHAO E,KRYCZEK I,et al.Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells[J].Gastroenterology,2014,147(6):1393-1404.
4、 PENG D,TANIKAWA T,LI W,et al.Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and NO/NOTCH cross-talk signaling[J].Cancer Res,2016,76(11):3156-3165. PENG D,TANIKAWA T,LI W,et al.Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and NO/NOTCH cross-talk signaling[J].Cancer Res,2016,76(11):3156-3165.
5、 GORDY J T,SANDHU A K,FESSLER K,et al.IFNalpha and 5-Aza-2’-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model[J].Front Immunol,2022(13):1074644. GORDY J T,SANDHU A K,FESSLER K,et al.IFNalpha and 5-Aza-2’-deoxycytidine combined with a dendritic-cell targeting DNA vaccine alter tumor immune cell infiltration in the B16F10 melanoma model[J].Front Immunol,2022(13):1074644.
6、 TU M M,ABDEL-HAFIZ H A,JONES R T,et al.Inhibition of the CCL2 receptor,CCR2,enhances tumor response to immune checkpoint therapy[J].Commun Biol,2020,3(1):720. TU M M,ABDEL-HAFIZ H A,JONES R T,et al.Inhibition of the CCL2 receptor,CCR2,enhances tumor response to immune checkpoint therapy[J].Commun Biol,2020,3(1):720.
7、 HIGHFILL S L,CUI Y,GILES A J,et al.Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy[J].Sci Transl Med,2014,6(237):237ra67. HIGHFILL S L,CUI Y,GILES A J,et al.Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy[J].Sci Transl Med,2014,6(237):237ra67.
8、 MACE T A,SHAKYA R,PITARRESI J R,et al.IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer[J].Gut,2018,67(2):320-332. MACE T A,SHAKYA R,PITARRESI J R,et al.IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer[J].Gut,2018,67(2):320-332.
9、 JIN K,PANDEY N B,POPEL A S.Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis[J].Breast Cancer Res,2018,20(1):54. JIN K,PANDEY N B,POPEL A S.Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis[J].Breast Cancer Res,2018,20(1):54.
10、 WEBER R,GROTH C,LASSER S,et al.IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy[J].Cell Immunol,2021(359):104254. WEBER R,GROTH C,LASSER S,et al.IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy[J].Cell Immunol,2021(359):104254.
11、 KIM K,SKORA A D,LI Z,et al.Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells[J].Proc Natl Acad Sci U S A,2014,111(32):11774-11779. KIM K,SKORA A D,LI Z,et al.Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells[J].Proc Natl Acad Sci U S A,2014,111(32):11774-11779.
12、 TANG H,LIANG Y,ANDERS R A,et al.PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression[J].J Clin Invest,2018,128(2):580-588. TANG H,LIANG Y,ANDERS R A,et al.PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression[J].J Clin Invest,2018,128(2):580-588.
13、 LAU J,CHEUNG J,NAVARRO A,et al.Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice[J].Nat Commun,2017(8):14572. LAU J,CHEUNG J,NAVARRO A,et al.Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice[J].Nat Commun,2017(8):14572.
14、 WEBER J,GIBNEY G,KUDCHADKAR R,et al.Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after Ipilimumab[J].Cancer Immunol Res,2016,4(4):345-353. WEBER J,GIBNEY G,KUDCHADKAR R,et al.Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after Ipilimumab[J].Cancer Immunol Res,2016,4(4):345-353.
15、 MEYER C,CAGNON L,COSTA-NUNES C M,et al.Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab[J].Cancer Immunol Immunother,2014,63(3):247-257. MEYER C,CAGNON L,COSTA-NUNES C M,et al.Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab[J].Cancer Immunol Immunother,2014,63(3):247-257.
16、 BINNEWIES M,ROBERTS E W,KERSTEN K,et al.Understanding the tumor immune microenvironment(TIME)for effective therapy[J].Nat Med,2018,24(5):541-550. BINNEWIES M,ROBERTS E W,KERSTEN K,et al.Understanding the tumor immune microenvironment(TIME)for effective therapy[J].Nat Med,2018,24(5):541-550.
17、 LIU Y,SUN Y,WANG P,et al.FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer[J].J Transl Med,2023,21(1):255. LIU Y,SUN Y,WANG P,et al.FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer[J].J Transl Med,2023,21(1):255.
18、 SUN R,LUO H,SU J,et al.Olaparib suppresses MDSC recruitment via SDF1alpha/CXCR4 axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice[J].Mol Ther,2021,29(1):60-74. SUN R,LUO H,SU J,et al.Olaparib suppresses MDSC recruitment via SDF1alpha/CXCR4 axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice[J].Mol Ther,2021,29(1):60-74.
19、 YU S J,MA C,HEINRICH B,et al.Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma[J].J Hepatol,2019,70(3):449-457. YU S J,MA C,HEINRICH B,et al.Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma[J].J Hepatol,2019,70(3):449-457.
20、 FLEET J C,BURCHAM G N,CALVERT R D,et al.1alpha,25 Dihydroxyvitamin D(1,25(OH)(2)D)inhibits the T cell suppressive function of myeloid derived suppressor cells(MDSC)[J].J Steroid Biochem Mol Biol,2020(198):105557. FLEET J C,BURCHAM G N,CALVERT R D,et al.1alpha,25 Dihydroxyvitamin D(1,25(OH)(2)D)inhibits the T cell suppressive function of myeloid derived suppressor cells(MDSC)[J].J Steroid Biochem Mol Biol,2020(198):105557.
21、 KO J S,RAYMAN P,IRELAND J,et al.Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained[J].Cancer Res,2010,70(9):3526-3536. KO J S,RAYMAN P,IRELAND J,et al.Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained[J].Cancer Res,2010,70(9):3526-3536.
22、 SANSONE P,BROMBERG J.Targeting the interleukin-6/Jak/stat pathway in human malignancies[J].J Clin Oncol,2012,30(9):1005-1014. SANSONE P,BROMBERG J.Targeting the interleukin-6/Jak/stat pathway in human malignancies[J].J Clin Oncol,2012,30(9):1005-1014.
23、 MIRZA N,FISHMAN M,FRICKE I,et al.All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients[J].Cancer Res,2006,66(18):9299-9307. MIRZA N,FISHMAN M,FRICKE I,et al.All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients[J].Cancer Res,2006,66(18):9299-9307.
24、 KUSMARTSEV S,CHENG F,YU B,et al.All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination[J].Cancer Res,2003,63(15):4441-4449. KUSMARTSEV S,CHENG F,YU B,et al.All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination[J].Cancer Res,2003,63(15):4441-4449.
25、 SHAYAN G,KANSY B A,GIBSON S P,et al.Phase Ib study of immune biomarker modulation with neoadjuvant cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals[J].Clin Cancer Res,2018,24(1):62-72. SHAYAN G,KANSY B A,GIBSON S P,et al.Phase Ib study of immune biomarker modulation with neoadjuvant cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals[J].Clin Cancer Res,2018,24(1):62-72.
26、 LI L,WANG L,LI J,et al.Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer[J].Cancer Res,2018,78(7):1779-1791. LI L,WANG L,LI J,et al.Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer[J].Cancer Res,2018,78(7):1779-1791.
27、 SERAFINI P,MECKEL K,KELSO M,et al.Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function[J].J Exp Med,2006,203(12):2691-2702. SERAFINI P,MECKEL K,KELSO M,et al.Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function[J].J Exp Med,2006,203(12):2691-2702.
28、 NAGARAJ S,YOUN J I,WEBER H,et al.Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer[J].Clin Cancer Res,2010,16(6):1812-1823. NAGARAJ S,YOUN J I,WEBER H,et al.Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer[J].Clin Cancer Res,2010,16(6):1812-1823.
29、 VINCENT J,MIGNOT G,CHALMIN F,et al.5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity[J].Cancer Res,2010,70(8):3052-3061. VINCENT J,MIGNOT G,CHALMIN F,et al.5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity[J].Cancer Res,2010,70(8):3052-3061.
30、 GUJAR S A,CLEMENTS D,DIELSCHNEIDER R,et al.Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms[J].Br J Cancer,2014,110(1):83-93. GUJAR S A,CLEMENTS D,DIELSCHNEIDER R,et al.Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms[J].Br J Cancer,2014,110(1):83-93.
31、 HAN B,MAO F Y,ZHAO Y L,et al.Altered NKp30,NKp46,NKG2D,and DNAM-1 Expression on circulating NK cells is associated with tumor progression in human gastric cancer[J].J Immunol Res,2018(2018):6248590. HAN B,MAO F Y,ZHAO Y L,et al.Altered NKp30,NKp46,NKG2D,and DNAM-1 Expression on circulating NK cells is associated with tumor progression in human gastric cancer[J].J Immunol Res,2018(2018):6248590.
32、 LI J,WANG L,CHEN X,et al.CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-beta-mTOR-HIF-1 signaling in patients with non-small cell lung cancer[J].Oncoimmunology,2017,6(6):e1320011. LI J,WANG L,CHEN X,et al.CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-beta-mTOR-HIF-1 signaling in patients with non-small cell lung cancer[J].Oncoimmunology,2017,6(6):e1320011.
33、 SINHA P,CLEMENTS V K,BUNT S K,et al.Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response[J].J Immunol,2007,179(2):977-983. SINHA P,CLEMENTS V K,BUNT S K,et al.Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response[J].J Immunol,2007,179(2):977-983.
34、 FENG S,CHENG X,ZHANG L,et al.Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers[J].Proc Natl Acad Sci U S A,2018,115(40):10094-10099. FENG S,CHENG X,ZHANG L,et al.Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers[J].Proc Natl Acad Sci U S A,2018,115(40):10094-10099.
35、 BRONTE V,BRANDAU S,CHEN S H,et al.Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards[J].Nat Commun,2016(7):12150. BRONTE V,BRANDAU S,CHEN S H,et al.Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards[J].Nat Commun,2016(7):12150.
36、 OSTRAND-ROSENBERG S,SINHA P.Myeloid-derived suppressor cells:linking inflammation and cancer[J].J Immunol,2009,182(8):4499-506. OSTRAND-ROSENBERG S,SINHA P.Myeloid-derived suppressor cells:linking inflammation and cancer[J].J Immunol,2009,182(8):4499-506.
37、 PLATTEN M,WICK W,van DEN EYNDE B J.Tryptophan catabolism in cancer:beyond IDO and tryptophan depletion[J].Cancer Res,2012,72(21):5435-5440. PLATTEN M,WICK W,van DEN EYNDE B J.Tryptophan catabolism in cancer:beyond IDO and tryptophan depletion[J].Cancer Res,2012,72(21):5435-5440.
38、 SRIVASTAVA M K,SINHA P,CLEMENTS V K,et al.Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine[J].Cancer Res,2010,70(1):68-77. SRIVASTAVA M K,SINHA P,CLEMENTS V K,et al.Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine[J].Cancer Res,2010,70(1):68-77.
39、 RODRIGUEZ P C,QUICENO D G,OCHOA A C.L-arginine availability regulates T-lymphocyte cell-cycle progression[J].Blood,2007,109(4):1568-1573. RODRIGUEZ P C,QUICENO D G,OCHOA A C.L-arginine availability regulates T-lymphocyte cell-cycle progression[J].Blood,2007,109(4):1568-1573.
40、 LIMAGNE E,RICHARD C,THIBAUDIN M,et al.Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients[J].Oncoimmunology,2019,8(4):e1564505. LIMAGNE E,RICHARD C,THIBAUDIN M,et al.Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients[J].Oncoimmunology,2019,8(4):e1564505.
41、 DENG J,LI J,SARDE A,et al.Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment[J].Cancer Immunol Res,2019,7(7):1079-1090. DENG J,LI J,SARDE A,et al.Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment[J].Cancer Immunol Res,2019,7(7):1079-1090.
42、 LU C,REDD P S,LEE J R,et al.The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells[J].Oncoimmunology,2016,5(12):e1247135. LU C,REDD P S,LEE J R,et al.The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells[J].Oncoimmunology,2016,5(12):e1247135.
43、 NOMAN M Z,DESANTIS G,JANJI B,et al.PD-L1 is a novel direct target of HIF-1alpha,and its blockade under hypoxia enhanced MDSC-mediated T cell activation[J].J Exp Med,2014,211(5):781-790. NOMAN M Z,DESANTIS G,JANJI B,et al.PD-L1 is a novel direct target of HIF-1alpha,and its blockade under hypoxia enhanced MDSC-mediated T cell activation[J].J Exp Med,2014,211(5):781-790.
44、 ZHANG H,MARIC I,DIPRIMA M J,et al.Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer[J].Blood,2013,122(7):1105-1113. ZHANG H,MARIC I,DIPRIMA M J,et al.Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer[J].Blood,2013,122(7):1105-1113.
45、 GABRILOVICH D I,OSTRAND-ROSENBERG S,BRONTE V.Coordinated regulation of myeloid cells by tumours[J].Nat Rev Immunol,2012,12(4):253-268. GABRILOVICH D I,OSTRAND-ROSENBERG S,BRONTE V.Coordinated regulation of myeloid cells by tumours[J].Nat Rev Immunol,2012,12(4):253-268.
46、 YOUN J I,COLLAZO M,SHALOVA I N,et al.Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice[J].J Leukoc Biol,2012,91(1):167-181. YOUN J I,COLLAZO M,SHALOVA I N,et al.Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice[J].J Leukoc Biol,2012,91(1):167-181.
47、 ELLIOTT L A,DOHERTY G A,SHEAHAN K,et al.Human tumor-infiltrating myeloid cells:phenotypic and functional diversity[J].Front Immunol,2017(8):86. ELLIOTT L A,DOHERTY G A,SHEAHAN K,et al.Human tumor-infiltrating myeloid cells:phenotypic and functional diversity[J].Front Immunol,2017(8):86.
48、 YOUN J I,NAGARAJ S,COLLAZO M,et al.Subsets of myeloid-derived suppressor cells in tumor-bearing mice[J].J Immunol,2008,181(8):5791-5802. YOUN J I,NAGARAJ S,COLLAZO M,et al.Subsets of myeloid-derived suppressor cells in tumor-bearing mice[J].J Immunol,2008,181(8):5791-5802.
49、 QIAN B Z,LI J,ZHANG H,et al.CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis[J].Nature,2011,475(7355):222-225. QIAN B Z,LI J,ZHANG H,et al.CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis[J].Nature,2011,475(7355):222-225.
50、 MARIGO I,BOSIO E,SOLITO S,et al.Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor[J].Immunity,2010,32(6):790-802. MARIGO I,BOSIO E,SOLITO S,et al.Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor[J].Immunity,2010,32(6):790-802.
51、 KUMAR V,PATEL S,TCYGANOV E,et al.The nature of myeloid-derived suppressor cells in the tumor microenvironment[J].Trends Immunol,2016,37(3):208-220. KUMAR V,PATEL S,TCYGANOV E,et al.The nature of myeloid-derived suppressor cells in the tumor microenvironment[J].Trends Immunol,2016,37(3):208-220.
52、 GABRILOVICH D I,NAGARAJ S.Myeloid-derived suppressor cells as regulators of the immune system[J].Nat Rev Immunol,2009,9(3):162-174. GABRILOVICH D I,NAGARAJ S.Myeloid-derived suppressor cells as regulators of the immune system[J].Nat Rev Immunol,2009,9(3):162-174.
53、 WU Y,YI M,NIU M,et al.Myeloid-derived suppressor cells:an emerging target for anticancer immunotherapy[J].Mol Cancer,2022,21(1):184. WU Y,YI M,NIU M,et al.Myeloid-derived suppressor cells:an emerging target for anticancer immunotherapy[J].Mol Cancer,2022,21(1):184.
54、 TOGASHI Y,SHITARA K,NISHIKAWA H.Regulatory T cells in cancer immunosuppression - implications for anticancer therapy[J].Nat Rev Clin Oncol,2019,16(6):356-371. TOGASHI Y,SHITARA K,NISHIKAWA H.Regulatory T cells in cancer immunosuppression - implications for anticancer therapy[J].Nat Rev Clin Oncol,2019,16(6):356-371.
55、 PAN Y,YU Y,WANG X,et al.Tumor-Associated Macrophages in Tumor Immunity[J].Front Immunol,2020(11):583084. PAN Y,YU Y,WANG X,et al.Tumor-Associated Macrophages in Tumor Immunity[J].Front Immunol,2020(11):583084.
56、 VINAY D S,RYAN E P,PAWELEC G,et al.Immune evasion in cancer:Mechanistic basis and therapeutic strategies[J].Semin Cancer Biol,2015,35 Suppl:S185-S98. VINAY D S,RYAN E P,PAWELEC G,et al.Immune evasion in cancer:Mechanistic basis and therapeutic strategies[J].Semin Cancer Biol,2015,35 Suppl:S185-S98.
57、 BEATTY G L,GLADNEY W L.Immune escape mechanisms as a guide for cancer immunotherapy[J].Clin Cancer Res,2015,21(4):687-692. BEATTY G L,GLADNEY W L.Immune escape mechanisms as a guide for cancer immunotherapy[J].Clin Cancer Res,2015,21(4):687-692.
58、 SIU L L,IVY S P,DIXON E L,et al.Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies[J].Clin Cancer Res,2017,23(17):4950-4958. SIU L L,IVY S P,DIXON E L,et al.Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies[J].Clin Cancer Res,2017,23(17):4950-4958.
59、 WEI G,ZHANG H,ZHAO H,et al.Emerging immune checkpoints in the tumor microenvironment:Implications for cancer immunotherapy[J].Cancer Lett,2021(511):68-76. WEI G,ZHANG H,ZHAO H,et al.Emerging immune checkpoints in the tumor microenvironment:Implications for cancer immunotherapy[J].Cancer Lett,2021(511):68-76.
60、 ZHANG Y,ZHANG Z.The history and advances in cancer immunotherapy:understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications[J].Cell Mol Immunol,2020,17(8):807-821. ZHANG Y,ZHANG Z.The history and advances in cancer immunotherapy:understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications[J].Cell Mol Immunol,2020,17(8):807-821.
1、杨钰萌.探索PD-1抑制剂联合氟尿嘧啶/铂类药物治疗胃癌患者的疗效预测模型[D].西安医学院,2025.DOI:10.27909/d.cnki.gxaxy.2025.000260. 杨钰萌.探索PD-1抑制剂联合氟尿嘧啶/铂类药物治疗胃癌患者的疗效预测模型[D].西安医学院,2025.DOI:10.27909/d.cnki.gxaxy.2025.000260.
上一篇
下一篇
作者登录
作者注册
审稿登录
编辑登录
最新资讯

“精神心理与脑科学：前沿与实践”专题征稿启事

发布于: 2026-05-29

“胶质瘤精准诊疗”专题征稿启事

发布于: 2026-05-29

“人工智能与医学融合”专题征稿启事

发布于: 2025-02-19

征稿 |《广州医药》—“医院管理”专栏征稿

发布于: 2025-01-21
学术活动

广州市第一人民医院烧伤整形美容与创面修复科举办首期EWMA创面管理与修复培训班

发布于: 2026-05-29

会议通知|人工智能赋能学科高质量发展专题讲座

发布于: 2025-02-19

提质增效，创新作为，不断提升麻醉服务能力2024工作总结与2025工作计划

发布于: 2025-02-19

2026年广州市医学会血液学分会学术年会暨再生障碍性贫血研讨会圆满落幕

发布于: 2026-06-01
出版者信息






《广州医药》公众号
目录
友情链接
关注微信公众号
首页   | 关于我们   | 联系我们  粤ICP备17084739号-3
关注微信公众号
粤ICP备17084739号-3